Abbott Japan LLC

Abbott Laboratories Corporation

The University of Tokyo

Abbott Japan Co. Ltd.

Eisaku Yoshida

Toru Yoshimura

Barry Lee Dowell

Gangamani S Beligere

Naohiko Koshikawa

Motoharu Seiki

Ryotaro Chiba

Disclosed herein are biomarkers for hepatocellular carcinoma and pancreatic cancer. The biomarkers may be laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof. Also disclosed herein are methods of diagnosing, prognosing, classifying risk, and monitoring progression of hepatocellular carcinoma or pancreatic cancer by the detecting the level of laminin gamma 2 monomer, PIVKA-II, AFP, CEA, CA19-9, or combinations thereof.

Methods of diagnosing hepatocellular carcinoma and pancreatic cancer

Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl, MgCl, and a sulfobetaine zwitterionic detergent.

Immunoassay methods and reagents for decreasing nonspecific binding

The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions.

Antibodies relating to PIVKA-II and uses thereof

Growing community of inventors

Chiba, Japan

Eisaku Yoshida